Generation of chimeric mice and Tc mice
Chimeric mice were produced from three ES (CYP3A-MAC) cell lines for the Tc line.
Chimera production was completed as described previously (2) . Briefly, ES cells were injected into eight-cell-stage embryos derived from ICR mice (CLEA, Tokyo, Japan) and then transferred into pseudopregnant ICR females. Five chimeric mice showing 100% coat-color chimerism were used to generate mice in which germline transmission could successfully occur in each line. Such mice were used in FISH and FCM analyses, and further mated with Cyp3a-KO mice to generate fully humanized CYP3A mice. The fully humanized CYP3A mice were used in RT-PCR and enzymatic functional assays. Representative data from these assays are shown in each figure. All animal experiments were approved by the Animal Care and Use Committee of Tottori University.
Preparation of Cas9 mRNA and gRNA
For rat Ugt2-KO, hCas9 mRNAs and gRNAs were prepared as reported previously (3) . A plasmid expressing hCas9 to which a T7 promoter and DNA encoding an SV40 nuclear localization signal had been added at the N-terminal was used (3) . Cas9 mRNA was transcribed in vitro using an mMESSAGE mMACHINE T7 Ultra Kit from linearized plasmids and was purified using a MEGAClear kit (Thermo Fisher Scientific, Waltham, MA, USA). Custom-designed gRNA targeting Ugt2 was obtained from Integrated DNA Technologies (Integrated DNA Technologies, Coralville, IA, USA).
TALEN mRNA preparation
TALEN plasmid construction and single-strand annealing (SSA) assay for the validation of TALEN activity were performed as described previously (4) . Briefly, TALEN plasmids were constructed by the two-step Golden Gate cloning method using the Golden Gate TALEN and TAL Effector Kit 2.0 (Addgene, Kit #1000000024) with the Yamamoto Lab TALEN Accessory Pack (Addgene, Kit #1000000030). The pcDNA-TAL-NC2 vector was used as a destination vector. The SSA assay was performed using a Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA). Each TALEN mRNA was prepared with mMESSAGE mMACHINE T7 Ultra Kit (Thermo Fisher Scientific, Waltham, MA, USA), following the manufacturer's instructions. Synthesized poly(A)-tailed TALEN mRNA was cleaned up using the RNeasy Mini kit (Qiagen, Hilden, Germany).
Genome editing by CRISPR/Cas9 or TALEN
CRISPR/Cas9 and TALEN were used to generate Ugt2 cluster KO and Cyp3a23/3a1/3a2 KO rats, respectively. In Ugt2 cluster KO, pronuclear-stage zygotes were collected from oviductal ampullae of F344/Stm female rats superovulated and mated with fertile male rats of the same strain. They were injected with Cas9 mRNA (100 ng/µl) and gRNA targeting the Ugt2 gene (50 ng/µl). Embryos were cultured for 24 h in mKRB medium at 37°C under 5% CO 2 in air. All of the surviving embryos were transferred into oviductal ampullae of pseudopregnant rats at 0.5 days postcoitum (24 embryos per recipient). Successful genome editing was confirmed by PCR using the Ugt2 junction primers (rUgt2 BD250 L/rUgt2 BD250 R) and sequencing of the product. In Cyp3a-KO, pronuclear-stage zygotes were collected from oviductal ampullae of Crlj:WI female rats superovulated and mated with fertile male rats of the same strain (5, 6) . They were injected with Cyp3a TALEN mRNA solution (10 ng/µl) and cultured for 24 h in mKRB medium at 37°C under 5% CO 2 in air. All of the surviving embryos were transferred into oviductal ampullae of pseudopregnant rats at 0.5 days postcoitum (24-28 embryos per recipient). Successful genome editing was confirmed by Cel-1 assay and sequencing of the Cyp3a gene. All animal experiments were approved by the Animal Care and Use Committee of National Institute for Physiological Sciences, Tottori University and Kyoto University.
Cel-1 assay
Primers used for the Cel-1 assay were TALEN rCyp3a L1/TALEN rCyp3a R1. PCR product was denatured and annealed for heteroduplex formation and then treated with Surveyor Nuclease S, Surveyor Enhancer S, and 15 mM MgCl 2 (IDT) for 1 h at 42°C.
Electrophoresis was performed using 2% agarose gel and DNA was visualized by ethidium bromide staining.
RT-PCR analyses
Total RNA from Tc tissue specimens was prepared using ISOGEN (Nippon Gene, Tokyo, Japan), purified using RNeasy columns (Qiagen), in accordance with the manufacturer's instructions, and then treated with RNase-free DNase I (Wako Pure Chemicals, Osaka, Japan). First-strand cDNA syntheses were completed using random hexamers and SuperScript III reverse transcriptase (Invitrogen). The primer pairs for detection of the expression of human UGT2 genes were as follows: for UGT2A3, UGT2A3-1L/UGT2A3-1R; for UGT2B4, UGT2B4-1L/UGT2B4-1R; for UGT2B7, UGT2B7-1L/UGT2B7-1R; for UGT2B10, UGT2B10-1L/UGT2B10-1R;
for UGT2B11, UGT2B11-1L/UGT2B11-1R; for UGT2B15, UGT2B15-2L/UGT2B15-2R; for UGT2B28, UGT2B28-1L/UGT2B28-1R; and for GAPDH, The primer pairs for detection of the expression of human CYP3A genes   were as follows: for CYP3A4, 3A4-2L/3A4-2R; and for CYP3A5, 3A5-1L/3A5-1R. GADPH was used as an internal control. The primer sequences for the RT-PCR analyses are described in Table S1 . cDNAs from C57BL/6 mouse and Wistar rat tissues were used as negative controls. PCR was completed with cDNAs using ExTaq (Takara Bio, Kusatsu, Japan), AmpliTaq Gold (Perkin Elmer, Waltham, MA, USA), or KOD FX (Toyobo, Tokyo, Japan). Amplifications were undertaken with an annealing temperature of 56-62°C for 25-35 cycles. Amplified fragments were then resolved by electrophoresis on 2% agarose gel, followed by staining with ethidium bromide.
Real-time RT-PCR
The cDNA synthesis was performed as mentioned above. Primer sequences for rat Ugt1a and Cyp genes were as described previously (7, 8) Sigma-Aldrich) was used as a typical CYP3A inducer in rodent. It was dissolved in corn oil (Sigma-Aldrich) and administered (i.p.) to mice and rats at 100 mg/kg for 4 days. Liver tissues from mice and rats were homogenized in ice-cold 1.15% KCl and microsomes were isolated as described previously (9, 10) . All animal experiments were approved by the Animal Care and Use Committee of Tottori University. Briefly, liver homogenate was centrifuged at 9,000 × g for 20 min at 4°C. The resultant supernatant was then ultra-centrifuged at 105,000 × g for 1 h at 4°C. The microsomal pellet was washed, resuspended in 100 mM sodium phosphate buffer (pH 7.4), and stored at −80°C until analyses. The method of extracting intestinal microsomal fractions was adapted from previous reports (11, 12) . The microsomal pellet was resuspended in 250 mM sucrose and stored at −80°C until analyses. Protein concentrations were determined using a DC protein assay kit (Bio-Rad), in accordance with the manufacturer's instructions. 
Preparation of microsomes from the liver and intestine

Zidovudine and gemfibrozil glucuronidation activity in vitro
Triazolam-hydroxylation activity in vitro
Triazolam was purchased from Wako Pure Chemicals. α-Hydroxy triazolam (α-OH triazolam) and 4-hydroxy triazolam (4-OH triazolam) were supplied by Nihon Upjohn Co. (Tokyo, Japan). Triazolam hydroxylation activity was determined as described previously (9, 10) . Briefly, the basic incubation mixture contained liver or intestinal 
Kinetics of triazolam and midazolam metabolism
Immunoinhibition of triazolam metabolism
The immunoinhibition assay of triazolam metabolism was achieved by the preincubation of liver microsomes of PCN-treated WT rats (2.5 µg), PCN-treated CYP3A-MAC/Cyp3a-KO rats (2.5 µg), or humans (25 µg) in the presence or absence of the specific antibody raised against human CYP3A4 (2.5 µl; #458334, BD Gentest) for 10 min at room temperature in a final volume of 25 µl. The preincubation mixtures were then diluted with a reaction mixture containing 200 µM triazolam, and the reactions were started by the addition of the NADPH-generating system in a final volume of 250 µl. Samples were incubated for an additional 20 min at 37°C. Fig. S1. Targeted truncation at AC125239 on hChr.4 . The wild-type locus of AC125239, pBS-TEL/AC125239Puro targeting construct, and the targeted allele are shown. With the targeting construct pBS-TEL/AC125239Puro, for the telomere-associated chromosomal truncation at the AC125239 locus on hChr.4, 2 of 96 drug-resistant clones selected in the presence of puromycin were targeted correctly, as shown by PCR (designated hChr.4-∆AC125239). figure. hChr.7-loxP-∆AC073842 in DT40 cells was introduced into CHO cells containing one of the MAC vectors (MAC1 with neomycin resistance gene, EGFP gene, and loxP) using microcellmediated chromosome transfer (MMCT) to obtain the hybrid CHO clones with two different exogenous chromosomes: the MAC1 and the modified hChr.7 (hChr.7-loxP-∆AC073842). To induce the reciprocal translocation between the MAC1 and the modified hChr.7, the Cre expression vectors were transfected to the CHO hybrids, and recombinant clones were selected using HAT over a period of 10 days. A total of 27 out of 42 drug-resistant clones were PCR-positive when using CYP3A cluster-, MAC-, and HPRT-reconstitution-specific primers. FISH analyses showed that the defined region of hChr.7 containing the CYP3A cluster had been cloned into the MAC1 vector in the CHO hybrid cells (designated CYP3A-MAC) (Fig. 2b) . S12 . PCR analyses to detect the disruption of Cyp3a23/3a1 and Cyp3a2 genes (a) Cel-1 assay to detect Cyp3a23/3a1 gene disruption. The transfer of 233 RNAinjected embryos resulted in the birth of 39 offspring (17%), 5 (13%) of which were determined to be genome-edited mutant rats by subsequent analyses. Tail genome of 37 F 0 rats was analyzed by Cel-1 assay for Cyp3a23/3a1. Mutations were observed in three rats, and two showed no band amplified by PCR for Cel-1 assay (red numbers), indicating a larger deletion over the PCR-detectable region (big deletion, BD). Sequence analyses revealed several mutants, namely, those with a 3-bp insertion and 1-bp, 9-bp, and 30-bp deletions compared to the wild-type (WT) allele. By mating heterozygous male and female rats of each line, we produced two independent homozygous BD mutants (derived from No. 32 and 58) and four independent homozygous insertion/deletion mutants including the 3-bp insertion (derived from No. 51), the 1-bp deletion (derived from No. 62), the 9-bp deletion, and the 30-bp deletion (each derived from No. 65). (b) Summary of Cyp3a23/3a1 and Cyp3a2 gene disruption. Liver microsomes of PCN-treated WT rats (n = 2), PCN-treated CYP3A-MAC/Cyp3a-KO rats (n = 2), or humans were preincubated with monoclonal antibody raised against human CYP3A4 (25 μL/100 μg of microsomal proteins of rat or 2.5 µL/100 µg of microsomal proteins of humans) at room temperature for 10 min. The preincubation mixture was then added to the reaction mixture containing triazolam (TRZ) (200 μM) and an NADPH-generating system and incubated at 37°C for 20 min for liver microsomes. Data are shown as % of control relative to the activity in the absence of antibody and are shown as the mean ± S.D. of three independent determinations. V max , K m and K s values were calculated by nonlinear least-squares method using models described in Supplementary Materials and Methods section by using the data shown in Fig. S18 . Numbers in parentheses represent S.D. from three determinations. Rats (n = 3 for each group) were orally administered triazolam (10 mg/kg for Cyp3a-KO and CYP3A-MAC/Cyp3a-KO, 20 mg/kg for WT). Blood were collected at 0.5, 1, 2, 4 and 8 hr after dosing. Plasma concentrations of triazolam and its metabolites (-OH triazolam and 4-OH triazolam) were determined by LC-MS/MS. Data are shown as the mean ± S.D. CYP3A-MAC/Cyp3a-KO rats were treated with PCN (100 mg/kg, 4 days) before triazolam administration.
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